Research Article| Volume 30, SUPPLEMENT 3, S92-S93, 2008

New developments in biomarkers for lysosomal storage disorders

  • Johannes M. Aerts
    Address correspondence to: Johannes M. Aerts, PhD, Department of Medical Biochemistry, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
    Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aerts JM
        • Hollak CE
        Plasma and metabolic abnormalities in Gaucher's disease.
        Baillieres Clin Haematol. 1997; 10: 691-709
        • Hollak CE
        • Evers L
        • Aerts JM
        • van Oers MH
        Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.
        Blood Cells Mol Dis. 1997; 23: 201-212
        • Michelakakis H
        • Spanou C
        • Kondyli A
        • et al.
        Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease.
        Biochim Biophys Acta. 1996; 1317: 219-222
        • Hollak CE
        • van Weely S
        • van Oers MH
        • Aerts JM
        Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
        J Clin Invest. 1994; 93: 1288-1292
        • Schoonhoven A
        • Rudensky B
        • Elstein D
        • et al.
        Monitoring of Gaucher patients with a novel chitotriosidase assay.
        Clin Chim Acta. 2007; 381: 136-139
        • Boot RG
        • Renkema GH
        • Verhoek M
        • et al.
        The human chitotriosidase gene. Nature of inherited enzyme deficiency.
        J Biol Chem. 1998; 273: 25680-25685
        • Boot RG
        • Verhoek M
        • de Fost M
        • et al.
        Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention.
        Blood. 2004; 103: 33-39
        • Deegan PB
        • Moran MT
        • McFarlane I
        • et al.
        Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.
        Blood Cells Mol Dis. 2005; 35: 259-267
        • van Breemen MJ
        • de Fost M
        • Voerman JS
        • et al.
        Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP- 1beta levels in type 1 Gaucher disease.
        Biochim Biophys Acta. 2007; 1772: 788-796
        • Vissers JP
        • Langridge JI
        • Aerts JM
        Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease.
        Mol Cell Proteomics. 2007; 6: 755-766
        • Groener JE
        • Poorthuis BJ
        • Kuiper S
        • et al.
        HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma.
        Clin Chem. 2007; 53: 742-747
        • Ghauharali-van der Vlugt K
        • Langeveld M
        • Poppema A
        • et al.
        Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.
        Clin Chim Acta. 2008; 389: 109-113
        • Aerts JM
        • Groener JE
        • Kuiper S
        • et al.
        Elevated globotriaosylsphingosine is a hallmark of Fabry disease.
        Proc Natl Acad Sci U S A. 2008; 105: 2812-2817